Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Equity (2020 - 2025)

Historic Return on Equity for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to 0.24%.

  • Tarsus Pharmaceuticals' Return on Equity rose 3000.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.55% for FY2024, which is 1500.0% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Return on Equity stood at 0.24%, which was up 3000.0% from 0.27% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Return on Equity high stood at 0.02% for Q2 2021, and its period low was 0.66% during Q4 2023.
  • Moreover, its 5-year median value for Return on Equity was 0.31% (2022), whereas its average is 0.35%.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Return on Equity plummeted by -3500bps in 2023 and then soared by 3000bps in 2025.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Return on Equity stood at 0.07% in 2021, then tumbled by -341bps to 0.31% in 2022, then crashed by -114bps to 0.66% in 2023, then increased by 26bps to 0.49% in 2024, then soared by 51bps to 0.24% in 2025.
  • Its Return on Equity was 0.24% in Q3 2025, compared to 0.27% in Q2 2025 and 0.36% in Q1 2025.